Oxford Nanopore Technologies, a UK-based developer of human genome technology, has raised £25m ($41m) from a consortium including its DNA sequencing marketing partner, Illumina UK. The other investors in Oxford Nanopore, which is valued in the round at £155m, included hedge fund Lansdowne Partners, London-listed developer of intellectual property-based businesses IP Group, mutual fund manager…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
